{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:04:14Z","timestamp":1793052254458,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00134-019-05801-z","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T17:26:23Z","timestamp":1571851583000},"page":"1503-1517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Vasopressor therapy in critically ill patients with shock"],"prefix":"10.1007","volume":"45","author":[{"given":"James A.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"issue":"6","key":"5801_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00134-018-5242-5","volume":"44","author":"D Annane","year":"2018","unstructured":"Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernandez G et al (2018) A global perspective on vasoactive agents in shock. Intensive Care Med 44(6):833\u2013846","journal-title":"Intensive Care Med"},{"issue":"9","key":"5801_CR2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00134-017-4821-1","volume":"43","author":"A Perner","year":"2017","unstructured":"Perner A, Gordon AC, Angus DC, Lamontagne F, Machado F, Russell JA et al (2017) The intensive care medicine research agenda on septic shock. Intensive Care Med 43(9):1294\u20131305","journal-title":"Intensive Care Med"},{"issue":"3","key":"5801_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","volume":"45","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45(3):486\u2013552","journal-title":"Crit Care Med"},{"issue":"3","key":"5801_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00134-018-5134-8","volume":"44","author":"HJ de Grooth","year":"2018","unstructured":"de Grooth HJ, Postema J, Loer SA, Parienti JJ, Oudemans-van Straaten HM, Girbes AR (2018) Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. Intensive Care Med 44(3):311\u2013322","journal-title":"Intensive Care Med"},{"issue":"17","key":"5801_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMe1402066","volume":"370","author":"JA Russell","year":"2014","unstructured":"Russell JA (2014) Is there a good MAP for septic shock? N Engl J Med 370(17):1649\u20131651","journal-title":"N Engl J Med"},{"issue":"10","key":"5801_CR6","first-page":"1760","volume":"13","author":"EA Vail","year":"2016","unstructured":"Vail EA, Gershengorn HB, Hua M, Walkey AJ, Wunsch H (2016) Epidemiology of vasopressin use for adults with septic shock. Ann Am Thorac Soc 13(10):1760\u20131767","journal-title":"Ann Am Thorac Soc"},{"key":"5801_CR7","unstructured":"Russell JA (2019) Shock syndromes related to sepsis. In: Chapter 100 in 26th edition Goldman-Cecil Textbook of Medicine (in press)"},{"issue":"3","key":"5801_CR8","first-page":"283","volume":"371","author":"P Asfar","year":"2014","unstructured":"Asfar P, Teboul JL, Radermacher P (2014) High versus low blood-pressure target in septic shock. N Engl J Med 371(3):283\u2013284","journal-title":"N Engl J Med"},{"issue":"19","key":"5801_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJMoa010307","volume":"345","author":"E Rivers","year":"2001","unstructured":"Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368\u20131377","journal-title":"N Engl J Med"},{"issue":"10","key":"5801_CR10","first-page":"995","volume":"377","author":"DC Angus","year":"2017","unstructured":"Angus DC (2017) Early, goal-directed therapy for septic shock\u2014a patient-level meta-analysis. N Engl J Med 377(10):995","journal-title":"N Engl J Med"},{"issue":"8","key":"5801_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8):801\u2013810","journal-title":"JAMA"},{"issue":"9","key":"5801_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877\u2013887","journal-title":"N Engl J Med"},{"issue":"6","key":"5801_CR13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/CCM.0000000000002323","volume":"45","author":"JA Russell","year":"2017","unstructured":"Russell JA, Lee T, Singer J, Boyd JH, Walley KR et al (2017) The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience. Crit Care Med 45(6):940\u2013948","journal-title":"Crit Care Med"},{"issue":"8","key":"5801_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","volume":"315","author":"CW Seymour","year":"2016","unstructured":"Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8):762\u2013774","journal-title":"JAMA"},{"issue":"5","key":"5801_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316(5):509\u2013518","journal-title":"JAMA"},{"issue":"5","key":"5801_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377(5):419\u2013430","journal-title":"N Engl J Med"},{"issue":"9","key":"5801_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1705716","volume":"378","author":"D Annane","year":"2018","unstructured":"Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S et al (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378(9):809\u2013818","journal-title":"N Engl J Med"},{"issue":"7","key":"5801_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jama.288.7.862","volume":"288","author":"D Annane","year":"2002","unstructured":"Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862\u2013871","journal-title":"JAMA"},{"issue":"2","key":"5801_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa071366","volume":"358","author":"CL Sprung","year":"2008","unstructured":"Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111\u2013124","journal-title":"N Engl J Med"},{"issue":"9","key":"5801_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1705835","volume":"378","author":"B Venkatesh","year":"2018","unstructured":"Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378(9):797\u2013808","journal-title":"N Engl J Med"},{"issue":"1","key":"5801_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13054-017-1798-7","volume":"21","author":"JA Russell","year":"2017","unstructured":"Russell JA, Vincent JL, Kjolbye AL, Olsson H, Blemings A, Spapen H et al (2017) Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care 21(1):213","journal-title":"Crit Care"},{"issue":"21","key":"5801_CR22","first-page":"2063","volume":"369","author":"DC Angus","year":"2013","unstructured":"Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369(21):2063","journal-title":"N Engl J Med"},{"issue":"2","key":"5801_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/01.CCM.0000048621.36569.69","volume":"31","author":"M Bucher","year":"2003","unstructured":"Bucher M, Kees F, Taeger K, Kurtz A (2003) Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia. Crit Care Med 31(2):566\u2013571","journal-title":"Crit Care Med"},{"issue":"2","key":"5801_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1164\/rccm.200903-0332OC","volume":"181","author":"TA Nakada","year":"2010","unstructured":"Nakada TA, Russell JA, Boyd JH, Aguirre-Hernandez R, Thain KR, Thair SA et al (2010) Beta2-adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 181(2):143\u2013149","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"5801_CR25","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1097\/CCM.0b013e318218665a","volume":"39","author":"TA Nakada","year":"2011","unstructured":"Nakada TA, Russell JA, Boyd JH, McLaughlin L, Nakada E, Thair SA et al (2011) Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 39(7):1641\u20131648","journal-title":"Crit Care Med"},{"issue":"5","key":"5801_CR26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1378\/chest.10-2517","volume":"139","author":"TA Nakada","year":"2011","unstructured":"Nakada TA, Russell JA, Wellman H, Boyd JH, Nakada E, Thain KR et al (2011) Leucyl\/cystinyl aminopeptidase gene variants in septic shock. Chest 139(5):1042\u20131049","journal-title":"Chest"},{"issue":"1","key":"5801_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","volume":"32","author":"A Lopez","year":"2004","unstructured":"Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S et al (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32(1):21\u201330","journal-title":"Crit Care Med"},{"issue":"27","key":"5801_CR28","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","volume":"329","author":"S Moncada","year":"1993","unstructured":"Moncada S, Higgs A (1993) The l-arginine-nitric oxide pathway. N Engl J Med 329(27):2002\u20132012","journal-title":"N Engl J Med"},{"issue":"13","key":"5801_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1056\/NEJM199703273361303","volume":"336","author":"GR Bernard","year":"1997","unstructured":"Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP et al (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Engl J Med 336(13):912\u2013918","journal-title":"N Engl J Med"},{"issue":"1","key":"5801_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2197-425X-1-2","volume":"1","author":"K Wagner","year":"2013","unstructured":"Wagner K, Wachter U, Vogt JA, Scheuerle A, McCook O, Weber S et al (2013) Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock. Intensive Care Med Exp 1(1):21","journal-title":"Intensive Care Med Exp"},{"issue":"5","key":"5801_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jcrc.2014.04.008","volume":"29","author":"HD Kanji","year":"2014","unstructured":"Kanji HD, McCallum J, Sirounis D, MacRedmond R, Moss R, Boyd JH (2014) Limited echocardiography-guided therapy in subacute shock is associated with change in management and improved outcomes. J Crit Care 29(5):700\u2013705","journal-title":"J Crit Care"},{"issue":"6","key":"5801_CR32","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589\u20131596","journal-title":"Crit Care Med"},{"issue":"23","key":"5801_CR33","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","volume":"376","author":"CW Seymour","year":"2017","unstructured":"Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS et al (2017) Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376(23):2235\u20132244","journal-title":"N Engl J Med"},{"issue":"11","key":"5801_CR34","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41591-018-0213-5","volume":"24","author":"M Komorowski","year":"2018","unstructured":"Komorowski M, Celi LA, Badawi O, Gordon AC, Faisal AA (2018) The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med 24(11):1716\u20131720","journal-title":"Nat Med"},{"issue":"4","key":"5801_CR35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/SHK.0000000000001281","volume":"52","author":"AA Udy","year":"2018","unstructured":"Udy AA, Finnis M, Jones D, Delaney A, Macdonald S, Bellomo R et al (2018) Incidence, patient characteristics, mode of drug delivery, and outcomes of septic shock patients treated with vasopressors in the arise trial. Shock 52(4):400\u2013407","journal-title":"Shock"},{"issue":"5","key":"5801_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1164\/rccm.201604-0862CP","volume":"194","author":"RF Stolk","year":"2016","unstructured":"Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox M (2016) Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med 194(5):550\u2013558","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"5801_CR37","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","volume":"34","author":"JA Myburgh","year":"2008","unstructured":"Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J et al (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34(12):2226\u20132234","journal-title":"Intensive Care Med"},{"issue":"9","key":"5801_CR38","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1097\/00003246-199609000-00024","volume":"24","author":"G Van den Berghe","year":"1996","unstructured":"Van den Berghe G, de Zegher F (1996) Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 24(9):1580\u20131590","journal-title":"Crit Care Med"},{"key":"5801_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09851-4","author":"SM Matt","year":"2019","unstructured":"Matt SM, Gaskill PJ (2019) Where is dopamine and how do immune cells see it?: dopamine-mediated immune cell function in health and disease. J Neuroimmune Pharmacol. https:\/\/doi.org\/10.1007\/s11481-019-09851-4","journal-title":"J Neuroimmune Pharmacol"},{"issue":"5","key":"5801_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000318531","volume":"2","author":"JA Russell","year":"2010","unstructured":"Russell JA, Walley KR (2010) Vasopressin and its immune effects in septic shock. J Innate Immun 2(5):446\u2013460","journal-title":"J Innate Immun"},{"issue":"1","key":"5801_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/ALN.0000000000001434","volume":"126","author":"LA Hajjar","year":"2017","unstructured":"Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA et al (2017) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology 126(1):85\u201393","journal-title":"Anesthesiology"},{"issue":"11","key":"5801_CR42","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/CCM.0000000000001853","volume":"44","author":"J Fisher","year":"2016","unstructured":"Fisher J, Douglas JJ, Linder A, Boyd JH, Walley KR, Russell JA (2016) Elevated plasma angiopoietin-2 levels are associated with fluid overload, organ dysfunction, and mortality in human septic shock. Crit Care Med 44(11):2018\u20132027","journal-title":"Crit Care Med"},{"issue":"4","key":"5801_CR43","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/cc7990","volume":"13","author":"A Morelli","year":"2009","unstructured":"Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V et al (2009) Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 13(4):R130","journal-title":"Crit Care"},{"issue":"11","key":"5801_CR44","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s00134-018-5267-9","volume":"44","author":"ZM Liu","year":"2018","unstructured":"Liu ZM, Chen J, Kou Q, Lin Q, Huang X, Tang Z et al (2018) Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med 44(11):1816\u20131825","journal-title":"Intensive Care Med"},{"key":"5801_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14607","author":"PF Laterre","year":"2019","unstructured":"Laterre PF, Berry SM, Blemings A, Carlsen JE, Francois B, Graves T et al (2019) Effect of selepressin vs placebo on ventilator-and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2019.14607","journal-title":"JAMA."},{"issue":"10","key":"5801_CR46","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/00003246-200110000-00002","volume":"29","author":"MY Kirov","year":"2001","unstructured":"Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B et al (2001) Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 29(10):1860\u20131867","journal-title":"Crit Care Med"},{"issue":"9588","key":"5801_CR47","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(07)61344-0","volume":"370","author":"D Annane","year":"2007","unstructured":"Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370(9588):676\u2013684","journal-title":"Lancet"},{"issue":"9","key":"5801_CR48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D De Backer","year":"2010","unstructured":"De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779\u2013789","journal-title":"N Engl J Med"},{"key":"5801_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40560-018-0344-2","volume":"6","author":"JA Russell","year":"2018","unstructured":"Russell JA, Wellman H, Walley KR (2018) Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. J Intensive Care 6:73","journal-title":"J Intensive Care"},{"issue":"5","key":"5801_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/phar.2105","volume":"38","author":"DA Hammond","year":"2018","unstructured":"Hammond DA, Ficek OA, Painter JT, McCain K, Cullen J, Brotherton AL et al (2018) Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy 38(5):531\u2013538","journal-title":"Pharmacotherapy"},{"issue":"1","key":"5801_CR51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13054-019-2427-4","volume":"23","author":"L Cheng","year":"2019","unstructured":"Cheng L, Yan J, Han S, Chen Q, Chen M, Jiang H et al (2019) Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials. Crit Care 23(1):168","journal-title":"Crit Care"},{"issue":"17","key":"5801_CR52","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1056\/NEJMoa1312173","volume":"370","author":"P Asfar","year":"2014","unstructured":"Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370(17):1583\u20131593","journal-title":"N Engl J Med"},{"issue":"20","key":"5801_CR53","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1001\/jama.2011.1615","volume":"306","author":"AJ Walkey","year":"2011","unstructured":"Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ (2011) Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 306(20):2248\u20132254","journal-title":"JAMA"},{"issue":"6","key":"5801_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/SHK.0000000000001022","volume":"49","author":"A Dargent","year":"2018","unstructured":"Dargent A, Nguyen M, Fournel I, Bourredjem A, Charles PE, Quenot JP et al (2018) Vasopressor cumulative dose requirement and risk of early death during septic shock: an analysis from the EPISS cohort. Shock 49(6):625\u2013630","journal-title":"Shock"},{"issue":"3","key":"5801_CR55","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1164\/rccm.201302-0355OC","volume":"188","author":"JA Russell","year":"2013","unstructured":"Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S et al (2013) Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 188(3):356\u2013364","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5801_CR56","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1053\/j.jvca.2018.04.006","volume":"32","author":"MW Dunser","year":"2018","unstructured":"Dunser MW, Bouvet O, Knotzer H, Arulkumaran N, Hajjar LA, Ulmer H et al (2018) Vasopressin in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 32(5):2225\u20132232","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"7","key":"5801_CR57","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2019.0071","volume":"321","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J et al (2019) Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA 321(7):654\u2013664","journal-title":"JAMA"},{"issue":"3","key":"5801_CR58","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jamia\/ocw138","volume":"24","author":"M Wu","year":"2017","unstructured":"Wu M, Ghassemi M, Feng M, Celi LA, Szolovits P, Doshi-Velez F (2017) Understanding vasopressor intervention and weaning: risk prediction in a public heterogeneous clinical time series database. J Am Med Inform Assoc 24(3):488\u2013495","journal-title":"J Am Med Inform Assoc"},{"issue":"13","key":"5801_CR59","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.2014.2637","volume":"311","author":"KM Kaukonen","year":"2014","unstructured":"Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000\u20132012. JAMA 311(13):1308\u20131316","journal-title":"JAMA"},{"issue":"8","key":"5801_CR60","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1097\/CCM.0000000000001843","volume":"44","author":"A Linder","year":"2016","unstructured":"Linder A, Lee T, Fisher J, Singer J, Boyd J, Walley KR et al (2016) Short-term organ dysfunction is associated with long-term (10-year) mortality of septic shock. Crit Care Med 44(8):e728\u2013e736","journal-title":"Crit Care Med"},{"issue":"9","key":"5801_CR61","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1164\/rccm.201806-1034OC","volume":"199","author":"C Permpikul","year":"2019","unstructured":"Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S (2019) Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med 199(9):1097\u20131105","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"5801_CR62","doi-asserted-by":"publisher","first-page":"e0129305","DOI":"10.1371\/journal.pone.0129305","volume":"10","author":"T Avni","year":"2015","unstructured":"Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A (2015) Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One 10(8):e0129305","journal-title":"PLoS One"},{"key":"5801_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019843664","author":"BE Menich","year":"2019","unstructured":"Menich BE, Miano TA, Patel GP, Hammond DA (2019) Norepinephrine and vasopressin compared with norepinephrine and epinephrine in adults with septic shock. Ann Pharmacother. https:\/\/doi.org\/10.1177\/1060028019843664","journal-title":"Ann Pharmacother"},{"issue":"4","key":"5801_CR64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00134-012-2468-5","volume":"38","author":"MW Dunser","year":"2012","unstructured":"Dunser MW, Festic E, Dondorp A, Kissoon N, Ganbat T, Kwizera A et al (2012) Recommendations for sepsis management in resource-limited settings. Intensive Care Med 38(4):557\u2013574","journal-title":"Intensive Care Med"},{"issue":"14","key":"5801_CR65","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2017.2841","volume":"317","author":"E Vail","year":"2017","unstructured":"Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H (2017) Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA 317(14):1433\u20131442","journal-title":"JAMA"},{"issue":"5","key":"5801_CR66","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1161\/01.HYP.30.5.1112","volume":"30","author":"K Yamamoto","year":"1997","unstructured":"Yamamoto K, Ikeda U, Okada K, Saito T, Kawahara Y, Okuda M et al (1997) Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. Hypertension 30(5):1112\u20131120","journal-title":"Hypertension"},{"issue":"2","key":"5801_CR67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000159082","volume":"32","author":"VM Rudichenko","year":"1995","unstructured":"Rudichenko VM, Beierwaltes WH (1995) Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res 32(2):100\u2013105","journal-title":"J Vasc Res"},{"issue":"8","key":"5801_CR68","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s001340101014","volume":"27","author":"CL Holmes","year":"2001","unstructured":"Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27(8):1416\u20131421","journal-title":"Intensive Care Med"},{"issue":"4","key":"5801_CR69","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00005373-199910000-00014","volume":"47","author":"MB Malay","year":"1999","unstructured":"Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47(4):699\u2013703 (discussion-5)","journal-title":"J Trauma"},{"issue":"3","key":"5801_CR70","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/00000542-200203000-00011","volume":"96","author":"BM Patel","year":"2002","unstructured":"Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96(3):576\u2013582","journal-title":"Anesthesiology"},{"issue":"9","key":"5801_CR71","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877\u2013887","journal-title":"N Engl J Med"},{"issue":"6","key":"5801_CR72","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","volume":"45","author":"M Nagendran","year":"2019","unstructured":"Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L et al (2019) Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med 45(6):844\u2013855","journal-title":"Intensive Care Med"},{"issue":"3","key":"5801_CR73","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CCM.0b013e3181961ace","volume":"37","author":"JA Russell","year":"2009","unstructured":"Russell JA, Walley KR, Gordon AC, Cooper DJ, Hebert PC, Singer J et al (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37(3):811\u2013818","journal-title":"Crit Care Med"},{"issue":"1","key":"5801_CR74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00134-009-1687-x","volume":"36","author":"AC Gordon","year":"2010","unstructured":"Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM et al (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36(1):83\u201391","journal-title":"Intensive Care Med"},{"issue":"8","key":"5801_CR75","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1097\/CCM.0000000000000333","volume":"42","author":"N Anantasit","year":"2014","unstructured":"Anantasit N, Boyd JH, Walley KR, Russell JA (2014) Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. Crit Care Med 42(8):1812\u20131820","journal-title":"Crit Care Med"},{"issue":"1","key":"5801_CR76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13054-018-2034-9","volume":"22","author":"K Jeon","year":"2018","unstructured":"Jeon K, Song JU, Chung CR, Yang JH, Suh GY (2018) Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS). Crit Care 22(1):131","journal-title":"Crit Care"},{"issue":"1","key":"5801_CR77","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/CCM.0000000000001380","volume":"44","author":"X He","year":"2016","unstructured":"He X, Su F, Taccone FS, Laporte R, Kjolbye AL, Zhang J et al (2016) A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med 44(1):23\u201331","journal-title":"Crit Care Med"},{"issue":"7","key":"5801_CR78","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1097\/CCM.0000000000000300","volume":"42","author":"MO Maybauer","year":"2014","unstructured":"Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wisniewska H, Traber LD et al (2014) The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med 42(7):e525\u2013e533","journal-title":"Crit Care Med"},{"issue":"5","key":"5801_CR79","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","volume":"18","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z et al (2014) Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 18(5):534","journal-title":"Crit Care"},{"issue":"1","key":"5801_CR80","first-page":"43","volume":"19","author":"LS Chawla","year":"2017","unstructured":"Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP et al (2017) Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc 19(1):43\u201349","journal-title":"Crit Care Resusc"},{"issue":"7","key":"5801_CR81","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1592\/phco.30.7.702","volume":"30","author":"CA Paciullo","year":"2010","unstructured":"Paciullo CA, McMahon Horner D, Hatton KW, Flynn JD (2010) Methylene blue for the treatment of septic shock. Pharmacotherapy 30(7):702\u2013715","journal-title":"Pharmacotherapy"},{"issue":"3","key":"5801_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1378\/chest.11-2604","volume":"142","author":"AC Gordon","year":"2012","unstructured":"Gordon AC, Wang N, Walley KR, Ashby D, Russell JA (2012) The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 142(3):593\u2013605","journal-title":"Chest"},{"issue":"17","key":"5801_CR83","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","volume":"375","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375(17):1638\u20131648","journal-title":"N Engl J Med"},{"issue":"6","key":"5801_CR84","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/01.CCM.0000063045.77339.B6","volume":"31","author":"D De Backer","year":"2003","unstructured":"De Backer D, Creteur J, Silva E, Vincent JL (2003) Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 31(6):1659\u20131667","journal-title":"Crit Care Med"},{"issue":"16","key":"5801_CR85","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jama.2013.278477","volume":"310","author":"A Morelli","year":"2013","unstructured":"Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310(16):1683\u20131691","journal-title":"JAMA"},{"issue":"3","key":"5801_CR86","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ajem.2017.11.013","volume":"36","author":"P Liu","year":"2018","unstructured":"Liu P, Wu Q, Tang Y, Zhou Z, Feng M (2018) The influence of esmolol on septic shock and sepsis: a meta-analysis of randomized controlled studies. Am J Emerg Med 36(3):470\u2013474","journal-title":"Am J Emerg Med"},{"issue":"7","key":"5801_CR87","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s00134-003-1810-3","volume":"29","author":"H Morimatsu","year":"2003","unstructured":"Morimatsu H, Uchino S, Chung J, Bellomo R, Raman J, Buxton B (2003) Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function. Intensive Care Med 29(7):1106\u20131112","journal-title":"Intensive Care Med"},{"issue":"17","key":"5801_CR88","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/CIRCULATIONAHA.117.030308","volume":"137","author":"AG Vedel","year":"2018","unstructured":"Vedel AG, Holmgaard F, Rasmussen LS, Langkilde A, Paulson OB, Lange T et al (2018) High-target versus low-target blood pressure management during cardiopulmonary bypass to prevent cerebral injury in cardiac surgery patients: a randomized controlled trial. Circulation 137(17):1770\u20131780","journal-title":"Circulation"},{"issue":"6","key":"5801_CR89","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0022-5223(98)70049-2","volume":"116","author":"M Argenziano","year":"1998","unstructured":"Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD et al (1998) Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 116(6):973\u2013980","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"5801_CR90","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1053-2498(99)00038-8","volume":"18","author":"M Argenziano","year":"1999","unstructured":"Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR et al (1999) Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 18(8):814\u2013817","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"5801_CR91","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0003-4975(99)01197-2","volume":"69","author":"DL Morales","year":"2000","unstructured":"Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW et al (2000) Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 69(1):102\u2013106","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"5801_CR92","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0003-4975(02)04408-9","volume":"75","author":"DL Morales","year":"2003","unstructured":"Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR et al (2003) A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 75(3):926\u2013930","journal-title":"Ann Thorac Surg"},{"issue":"19 Suppl","key":"5801_CR93","first-page":"II182","volume":"100","author":"EB Rosenzweig","year":"1999","unstructured":"Rosenzweig EB, Starc TJ, Chen JM, Cullinane S, Timchak DM, Gersony WM et al (1999) Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 100(19 Suppl):II182\u2013II186","journal-title":"Circulation"},{"key":"5801_CR94","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1749-8090-8-49","volume":"8","author":"H Yimin","year":"2013","unstructured":"Yimin H, Xiaoyu L, Yuping H, Weiyan L, Ning L (2013) The effect of vasopressin on the hemodynamics in CABG patients. J Cardiothorac Surg 8:49","journal-title":"J Cardiothorac Surg"},{"issue":"1","key":"5801_CR95","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/ALN.0000000000001434","volume":"126","author":"AM Hajjar","year":"2016","unstructured":"Hajjar AM, Vincent JL, Galas FRBG, Rhodes A, Landonni G, Osawa EA et al (2016) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCSS randomized controlled trial. Anesthesiology 126(1):85\u201393","journal-title":"Anesthesiology"},{"issue":"4","key":"5801_CR96","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/aas.13089","volume":"62","author":"MH Moller","year":"2018","unstructured":"Moller MH, Granholm A, Junttila E, Haney M, Oscarsson-Tibblin A, Haavind A et al (2018) Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 62(4):420\u2013450","journal-title":"Acta Anaesthesiol Scand"},{"key":"5801_CR97","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MCC.0000000000000624","volume":"25","author":"S van Diepen","year":"2019","unstructured":"van Diepen S, Thiele H (2019) An overview of international cardiogenic shock guidelines and application in clinical practice. Curr Opin Crit Care 25:365\u2013370","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"5801_CR98","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","volume":"72","author":"B Levy","year":"2018","unstructured":"Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G et al (2018) Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 72(2):173\u2013182","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"5801_CR99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ccc.2017.08.005","volume":"34","author":"JA Russell","year":"2018","unstructured":"Russell JA, Rush B, Boyd J (2018) Pathophysiology of septic shock. Crit Care Clin 34(1):43\u201361","journal-title":"Crit Care Clin"},{"issue":"1","key":"5801_CR100","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13054-019-2347-3","volume":"23","author":"DR Spahn","year":"2019","unstructured":"Spahn, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ et al (2019) The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 23(1):98","journal-title":"Crit Care"},{"issue":"10","key":"5801_CR101","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1097\/CCM.0000000000003276","volume":"46","author":"JA Silversides","year":"2018","unstructured":"Silversides JA, Fitzgerald E, Manickavasagam US, Lapinsky SE, Nisenbaum R, Hemmings N et al (2018) Deresuscitation of patients with iatrogenic fluid overload is associated with reduced mortality in critical illness. Crit Care Med 46(10):1600\u20131607","journal-title":"Crit Care Med"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-019-05801-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:58:49Z","timestamp":1744178329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-019-05801-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["5801"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05801-z","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell was a founder, Director and shareholder in Cyon Therapeutics Inc. Dr. Russell is a shareholder in Molecular You Corp.Dr. Russell reports receiving consulting fees in the past 3\u00a0years from: (1) Asahi Kesai Pharmaceuticals of America (AKPA) (developing recombinant thrombomodulin in sepsis). (2) SIB Therapeutics LLC (developing a sepsis drug). (3) Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). No longer actively consulting for the following: (4) La Jolla Pharmaceuticals (developing angiotensin II; Dr. Russell chaired the DSMB of a trial of angiotensin II from 2015 to 2017)\u2014no longer actively consulting. (5) Grifols (sells albumin)\u2014no longer actively consulting. PAR Pharma (sells prepared bags of vasopressin)\u2014no longer actively consulting.Dr. Russell reports having received an investigator-initiated grant from Grifols (entitled \u201cIs HBP a mechanism of albumin\u2019s efficacy in human septic shock?\u201d) that was provided to and administered by UBC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}